New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Gregory DiNoia Biography and Net Worth

SVP of Mesa Laboratories

Greg DiNoia joined the Company in November 2017 as Senior Vice President. From 2008 through November 2017, Greg held several positions with Danaher Corporation (“Danaher”). During his Danaher tenure, Greg served as Global Vice President at Trojan Technologies, North American Vice President of Sales, Service and Customer Support at Hach, and Vice President and General Manager of North American Sales at Gilbarco Veeder Root all of which are wholly owned subsidiaries of Danaher. From 1997 to 2008, Greg was Vice President, Americas for Metrologic Instruments.

What is Gregory DiNoia's net worth?: The estimated net worth of Gregory DiNoia is at least $256,465.89 as of June 16th, 2021. Mr. DiNoia owns 2,529 shares of Mesa Laboratories stock worth more than $256,466 as of November 21st. This net worth approximation does not reflect any other investments that Mr. DiNoia may own. Learn More about Gregory DiNoia's net worth.
How do I contact Gregory DiNoia?: The corporate mailing address for Mr. DiNoia and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on Gregory DiNoia's contact information.
Has Gregory DiNoia been buying or selling shares of Mesa Laboratories?: Gregory DiNoia has not been actively trading shares of Mesa Laboratories in the last ninety days. Most recently, Gregory Dinoia sold 280 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $323.72, for a transaction totalling $90,641.60. Learn More on Gregory DiNoia's trading history.
Who are Mesa Laboratories' active insiders?: Mesa Laboratories' insider roster includes Brian Archbold (SVP), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), and John Sullivan (Director). Learn More on Mesa Laboratories' active insiders.
Are insiders buying or selling shares of Mesa Laboratories?: During the last twelve months, insiders at the medical instruments supplier sold shares 3 times. They sold a total of 5,517 shares worth more than $642,010.16. The most recent insider tranaction occured on October, 28th when CEO Gary M Owens sold 2,518 shares worth more than $286,095.16. Insiders at Mesa Laboratories own 4.4% of the company. Learn More about insider trades at Mesa Laboratories.
Information on this page was last updated on 10/28/2024.

Gregory DiNoia Insider Trading History at Mesa Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2021	Sell	280	$323.72	$90,641.60
6/16/2021	Sell	1,211	$255.67	$309,616.37	2,529
6/4/2021	Sell	540	$260.27	$140,545.80	1,380
10/2/2020	Sell	332	$260.00	$86,320.00	1,452
9/4/2020	Sell	280	$243.55	$68,194.00	1,182
8/17/2020	Sell	835	$245.70	$205,159.50	2,297

Gregory DiNoia Buying and Selling Activity at Mesa Laboratories

Mesa Laboratories Company Overview

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Today's Range

Now: $101.41

$98.82

$102.92

50 Day Range

MA: $122.05

$98.59

$135.91

2 Week Range

Now: $101.41

$83.68

$141.17

Volume

41,352 shs

Average Volume

41,274 shs

Market Capitalization

$550.66 million

P/E Ratio

N/A

Dividend Yield

0.64%

Beta

0.87